Further, TRAIL-R2-targeting agents are of particular interest in glioblastoma because of frequent epigenetic inactivation of TRAIL-R1 in this tumor.18 As Smac mimetics as well as proapoptotic TRAIL receptor agonists are currently under evaluation in early clinical trials,16, 38 it may in principle be feasible to transfer this combination approach to the clinical stage. Here, TNFRSF10A is linked to neoplasm.